Laurence Chu, MD
Otolaryngology · Austin, TXNPI 1902854680
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,849 of the $8,465 with a category attached, or 69.1%. 9 manufacturers reported payments, led by Modernatx, Inc. at 57.5% of the total.
Across 65 payments — averaging $130.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$5K
- Pfizer$2K
- Seqirus USA Inc$824
- Sanofi$281
- Regeneron Healthcare Solutions, Inc.$147
- Stryker$39
- plus $52 from 3 others
Across 3,378 payments — averaging $11,086 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$18.7M
- Pfizer$14.1M
- Novavax Inc$1.6M
- Sanofi Pasteur Inc.$1.1M
- Janssen Research & Development, LLC$783K
- GSK$489K
- plus $698K from 6 others
What the payments were for
- Travel & lodging$5,84969%
- Food & beverage$2,59631%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 26 | $4,863 |
| Pfizer | 9 | $2,259 |
| Seqirus USA Inc | 4 | $824 |
| Sanofi | 20 | $281 |
| Regeneron Healthcare Solutions, Inc. | 2 | $147 |
| Stryker | 1 | $39 |
| Novavax Inc | 1 | $23 |
| Acclarent, Inc | 1 | $15 |
| Intersect ENT, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,465 in reported general payments places this provider in the 85th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 20 | $270 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $146 |
| Prednisone | 13 | $18 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Austin
- Daniel SlaughterAustin$18K
- Karen StiermanAustin$17K
- Marc DeanFort Worth$486K
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ronald KuppersmithCollege Station$325K
- Ron KarniHouston$317K
- Philip ChenSan Antonio$305K
- Jordan RihaniSouthlake$280K
- Keith MathenyFrisco$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.